Formerly dba Qgenics Inc, and then Protein Discovery Inc, after merger of the firm in 2011 with Expedeon Inc, the combined entity operated under the Expedeon name. With expertise in cutting-edge innovative reagents and services for life sciences and diagnostics, having application across workflows including: protein electrophoresis; liquid biopsy; whole genome amplification; antibody- and protein-labeling; and immunoassay development, the firm's offerings include(d) off-the-shelf products, and custom services, supporting scientists working in the life sciences and diagnostic industries. In June 2017 the firm was acquired by the publicly traded German firm SYGNIS Pharma AG.(ETR:LIO1) (aka Lion Bioscience) organized around development of drugs for treatment of disorders of the central nervous system (CNS)
